Therapy News and Research

RSS

TransCytos, Enginasion collaborate to develop new transfection technology

Enginasion and TransCytos announced today that their collaboration has resulted in a prototype 'transfection' technology that is designed to have a dramatic and positive impact on the drug-research industry.

22 May 2012

Intermountain signs collaborative research agreement with Myriad

Intermountain Healthcare and Myriad Genetics today announced they have signed a collaborative research agreement. The purpose of this agreement is to perform research and validation studies on transformative molecular diagnostic tests being developed by Myriad in an effort to improve the care and treatments for patients at Intermountain and around the world.

22 May 2012

Combination of vitamin D and BCG vaccine improves bladder cancer survival

The tuberculosis vaccine is often used as a treatment for bladder cancer, and adding vitamin D might improve the vaccine's effectiveness, according to new research from the University of Rochester Medical Center presented today at the American Urological Association annual meeting.

22 May 2012

HSF-1 protein likely source of chemotherapy-related heart damage in mice

Blocking a protein in the heart that is produced under stressful conditions could be a strategy to prevent cardiac damage that results from chemotherapy, a new study suggests.

22 May 2012

MGH develops new technique to reconstruct the larynx after surgery for advanced cancer

Massachusetts General Hospital (MGH) surgeons have developed a new technique for reconstructing the larynx after surgery for advanced cancer.

22 May 2012

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents.

22 May 2012

Study finds large amounts of melanopsin in the human brain

A new study by Oulu University found large amounts of a light-sensitive OPN4-protein, melanopsin, in the human brain.

22 May 2012

FDA clears Teleflex’s ARROW PICC with Chloragard technology

Teleflex Incorporated announced today that in addition to broad-spectrum antimicrobial protection, the pressure-injectable ARROW PICC with Chloragard Technology provides antithrombogenic protection for at least 30 days.

22 May 2012

More than 16,000 patients visit NYU Langone's new CMC

If the first month at NYU Langone's new Center for Musculoskeletal Care (CMC) is any indication of the growing need for integrated care, the more than 16,000 patients coming to the facility on 38th Street in Manhattan since it opened in April is a true testament.

22 May 2012

CHDI, Lundbeck enter collaboration to investigate targeted therapy for Huntington's disease

CHDI Foundation, Inc. and Lundbeck today announced a research collaboration to investigate a targeted therapy for Huntington's disease (HD). Currently, no treatment exists to slow or halt the progression of HD, a challenging hereditary neurodegenerative disease characterized by a triad of behavioral, cognitive, and motor symptoms.

21 May 2012

New therapeutic options for management of melanoma brain metastases

In a recent article published in MELANOMA RESEARCH and a subsequent commentary in British medical journal THE LANCET, researchers at Moffitt Cancer Center discussed new therapeutic options for the management of melanoma brain metastases. Patients with advanced melanoma are at high risk for developing brain metastases. Once brain metastases are present, these patients tend to have poor outcomes.

21 May 2012

$Children with pelvic and thigh fractures rarely develop dangerous blood clots$

Children with pelvic and thigh fractures rarely develop dangerous blood clots

Children with pelvic and thigh fractures develop dangerous blood clots so rarely that anti-clotting therapy should be given only to those with underlying conditions that increase clotting risk, according to a study from Johns Hopkins Children's Center.

21 May 2012

Young children with cystic fibrosis do not benefit from concentrated saline therapy

Concentrated saline therapy not effective in young children with cystic fibrosis NIH-funded study demonstrates importance of conducting pediatric clinical trials.

21 May 2012

Massage therapy effective for knee osteoarthritis, chronic low back pain and fibromyalgia

A growing body of evidence shows massage therapy can be effective for a variety of prevalent health conditions, including the pain of osteoarthritis of the knee, inflammation after exercise, chronic low back pain and fibromyalgia.

21 May 2012

Opexa's Tovaxin for MS is now Tcelna

Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company is rebranding its leading MS therapy with the new name Tcelna. The product, previously known as Tovaxin, will now be known as Tcelna as the company positions itself towards the treatment of patients with Secondary Progressive MS (SPMS).

21 May 2012

New trial on home oxygen therapy for patients with chronic heart failure

Researchers at the University of Hull, in the UK, have just launched a major new trial investigating the effects of home oxygen therapy in patients with chronic heart failure (CHF).

21 May 2012

TTFields therapy vs. chemotherapy in patients with recurrent glioblastoma

Results of the first randomized controlled trial to compare a novel cancer treatment modality delivering Tumor Treating Fields (TTFields) therapy versus chemotherapy in patients with recurrent glioblastoma (GBM) were published in the European Journal of Cancer.

21 May 2012

Deletion of 'lunatic fringe' promotes tumor formation of basal-like breast cancers

Multiple research projects - including a 2006 study conducted at the University of North Carolina at Chapel Hill - have used DNA microarray analysis to identify several breast cancer subtypes, including luminal A, luminal B, basal-like and HER2-enriched.

21 May 2012

Regenerative medicine researchers explore innovative ways to treat childhood conditions

About 3 percent of the babies born in the United States have a birth defect. Children without a birth defect are also susceptible to injury or disease. At The University of Texas Health Science Center at Houston (UTHealth), regenerative medicine researchers are exploring innovative ways to treat these conditions.

21 May 2012

Pantera Lux Paclitaxel Releasing Balloon highly promising for DES restenosis

Six-month results from the DELUX registry demonstrating excellent safety and efficacy results for the Pantera Lux Paclitaxel Releasing Balloon in more than 1000 patients were presented by Ralph Toelg, MD, Segeberger Heart Center Clinic, Germany, and Thomas Schmitz, MD, Elisabeth Hospital, Germany, at the EuroPCR 2012 congress in Paris last week.

21 May 2012